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Abstract
Background: HIV infection affects the populations of T helper cells, dendritic cells and macrophages. Moreover, it has a
serious impact on the central nervous system. It is yet not clear whether this list is complete and why specifically those cell
types are affected. To address this question, we have developed a method to identify cellular surface proteins that permit,
mediate or enhance HIV infection in different cell/tissue types in HIV-infected individuals. Receptors associated with HIV
infection share common functions and domains and are involved in similar cellular processes. These properties are exploited
by bioinformatics techniques to predict novel cell surface proteins that potentially interact with HIV.
Methodology/Principal Findings: We compiled a set of surface membrane proteins (SMP) that are known to interact with
HIV. This set is extended by proteins that have direct interaction and share functional similarity. This resulted in a
comprehensive network around the initial SMP set. Using network centrality analysis we predict novel surface membrane
factors from the annotated network. We identify 21 surface membrane factors, among which three have confirmed
functions in HIV infection, seven have been identified by at least two other studies, and eleven are novel predictions and
thus excellent targets for experimental investigation.
Conclusions: Determining to what extent HIV can interact with human SMPs is an important step towards understanding
patient specific disease progression. Using various bioinformatics techniques, we generate a set of surface membrane
factors that constitutes a well-founded starting point for experimental testing of cell/tissue susceptibility of different HIV
strains as well as for cohort studies evaluating patient specific disease progression.
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Introduction
One of the important characteristics of Human Immu-
nodeficiency Virus (HIV) is its ability to interact with many
cell types and its capacity to alter the function of chemokines
that otherwise work in harmony with the immune system. This
interaction depends on the phenotype of the virus, the receptor
type residing on the cell as well as the chemokines present
in the environment. The main factor determining its com-
plex interaction profile is HIV’s highly interactive proteome.
Structurally, its genome has evolved to interact with many
human proteins from various cellular pathways. Therefore, each
infectious virion consists of viral proteins, such as Tat, Gp120
or Nef, which interact with proteins inside and outside the cell
[1–3].
Another contributor to this complex behavior is the high degree
of phenotypic variation in the HIV population in-vivo [4].
Interestingly, each transmission event (between individuals)
introduces an evolutionary bottleneck since the majority of new
infections is usually initiated with a single virus [5].
Typically, HIV infection is thought to originate from the
contact of genital epithelia with the infectious virions. It has been
suggested that Langerhans cells and resident dendritic cells of
stratified squamous epithelia serve as the initial targets of HIV
infection [6,7]. Virions are mobilized to the lymph nodes either via
attachment of the HIV Gp120 to the DC-SIGN receptor
expressed on dendritic cells (DCs) [6] or by direct infection of
DCs within epithelia via CD4 and CCR5 receptors [7]. In the
lymph nodes virions are transferred to CD4+ T cells and
macrophages.
Moreover, soluble Gp120 binds to Immunoglobulin-E on innate
immune system cells, such as basophils, mast cells and monocytes,
and induces the secretion of cytokines thereby causing further
activation of type-2 T-helper cells (Th2), the primary targets of
HIV-1 infection [8]. The system-wide activation of CD4+ T cells
results in an increased number of infected cells and high viral
reproduction that leads to viral peaks observed in the primary
stages of the infection. This translates into virus populations, which
essentially are genotypically related cloud(s) of phenotypes (or
quasispecies). The infection, which has been ignited with a
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types harbouring immune system cells, such as CD4+CCR5+
CCR3+ microglia and macrophages [9], or hMR+ astrocytes [10],
megakaryocytes [11] and monocytes [12].
A puzzling fact is that the cell types which are targets of HIV
infection have different receptor expression profiles and do not
necessarily harbor main co-receptors CCR5 or CXCR4. For
instance, in a clinical study with a heterozygote CCR5-D32
(CCR5 delta 32) individual (which gives partial resistance to
infection via CCR5 tropic viruses) a wide range of co-receptor
usage is observed, suggesting the involvement of other surface
membrane factors [13].
Furthermore, binding of HIV to cell surface factors other than
CD4 and chemokine receptors does not always permit viral entry
but leads to endocytosis of the viral particles. This promotes
relocation of the infectious virions, future trans-infection of
adjacent cells [14] and leads to the activation of the immune
system. Therefore, it is imperative to bear in mind that there are
surface membrane factors interacting with HIV proteins, hence
affecting the course of infection indirectly.
Another important point regarding surface membrane proteins
is that their interactions with HIV-1 proteins are not only
restricted to the extracellular environment. Events taking place
inside and outside the cell membrane are neither decoupled
processes, nor mutually exclusive. In vitro studies with HIV-1
protein Tat have shown that Tat is able to induce the intrinsic
pathway of apoptosis in a number of human cell lines in addition
to up-regulating the expression of co-receptor CCR5 and the
interleukin-2 (IL-2) in HIV-1-infected cells. Extracellular Tat has
also been shown to induce neuronal death by binding to the
lipoprotein receptor-related protein (LRP) (see Romani et al. [15]
for an extended review).
Although many steps of the virus life cycle have been unraveled
and 24 distinct drugs targeted against HIV have been approved,
all efforts to achieve an overall eradication of the virus have turned
out to be ineffective [16]. However, life expectancy under highly
active antiretroviral therapy (HAART) treatment has been
extended to 21.5 years [17].
The missing piece of the puzzle
These observations lead to the following questions: What is the
extent of surface membrane factors contributing to HIV-1
infection and how do they influence the outcome of the treatment?
HIV exploits the existing signaling and regulatory pathways in
its host. The different receptors or surface membrane proteins that
are targeted in different cell types are likely to be involved in the
same (or closely related) functional pathways, because the range of
processes and pathways available to the virus is limited. The
complexity in finding the right factors arises from the fact that
there are several hundreds of surface membrane proteins
expressed on a wide variety of cells.
Experimental testing of hundreds of targets from numerous
pathways is not feasible. Therefore, we developed a computational
approach that generates high quality hypotheses for wet-lab
experiments with the aim to identify surface membrane host
factors contributing to HIV-1 disease outcome. We adapt a
strategy from disease gene discovery that is based on protein
interaction, network centrality and functional similarity to
receptors that are known to interact with HIV. We infer promising
candidates using measures of centrality in the emerging network of
proteins. This method reproduces reported factors, such as CCR1,
CCBP2 and CD97, but also results in a list of promising proteins
that likely affect the progression of the infection.
Materials and Methods
We designed a method to identify uncharacterized surface
membrane factors interacting with HIV. We employ a ranking
strategy based on network centrality that uses documented HIV
receptors, human protein interaction data and protein functions.
The algorithm is partially adapted from disease gene identification
strategies that infer gene-disease associations from similarity
networks and their properties. Its underlying principle is based
on the assumption that the most central genes/proteins in a
specific disease network are likely to be related to the disease
[18,19].
Conceptual design
For identifying novel surface membrane factors we developed a
generic framework that infers candidate genes or proteins based on
their similarity to a set of reported genes or gene products of
interest. The general workflow of this framework, illustrated in
Figure 1, comprises three steps. First, a seed set is defined by genes/
proteins that share specific characteristics of interest which will be
later used for growing a functional interaction network. This can
be a set of proteins associated with a certain disease, involved in
specific pathways, sharing other biological properties or transcripts
that are differentially expressed in a condition of interest. In the
second step, candidate proteins are extracted based on their
functional similarity to the seed set and a domain-specific similarity
network is generated by extending this set by all functionally related
proteins. The notion of similarity is not necessarily restricted to
functional annotation or interaction data but rather can cover any
kind of genomic data, such as expression data, SNPs, sequences
and phenotypes. Finally, in the last step network centrality analysis is
performed to rank those proteins with respect to their relative
importance within the network. The most central ones are
presumed to be of functional importance for the specific network.
Note that for simplicity we only referred to proteins in the
description of the framework. However, our method is not
restricted to proteins but is also applicable to genes depending on
the biological question.
Translating the general framework into the context of
identifying surface membrane factors interacting with HIV-1
implies that proteins, which are related to known HIV receptors
through functional similarity or interaction with the same ligand(s),
tend to be part of the same pathway and often share the same
biological function. Therefore, if a network is built based on
documented surface membrane factors that is extended with
related genes, yet undiscovered surface proteins should also be
central in the resulting network. To study this, we build an
enriched HIV receptor network from known HIV receptors and
rank all its proteins according to their centrality within the
network. Highly ranked proteins are further analyzed to identify
potentially novel surface membrane factors.
Below we explain the details of our method for identifying
surface membrane factors interacting with HIV-1. One should
keep in mind that the framework is neither domain nor disease
specific and can be applied for various biological questions other
than the one presented in this study.
Data
We use a set of known HIV receptors, their functional
annotations and human protein interaction data as a scaffold for
building an HIV receptor network. The initial list is compiled by
mining the literature and the ‘HIV-1, Human Protein Interaction
Database’ [20]. A receptor is included if it is reported by at least
two independent studies. This applies to 16 HIV receptors.
Receptors of HIV Infection
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not documented in the data gathered from protein interaction
databases (see below) and thus have not been used in this study.
Table 1 shows the final list of 13 HIV receptors including protein
domain information (InterPro), literature references and their role
in HIV infection. The list covers established receptors such as
CD4 and DC-SIGN, HIV co-receptors CCR5 and CXCR4 as
well as alternative co-receptors CCR2 and CCR3. Only recently
reported co-receptors, such as XCR1 [21], have not yet been
included since they were not documented by the time the study
was conducted. However, we use a list of cell surface proteins that
are reported to interact with HIV in a broad sense. Therefore, we
do not limit our prediction method to receptors that only permit
the entry of HIV into the primary cells.
Human protein interactions were obtained from the major
public protein-protein interaction databases: DIP [22], IntAct
[23], BIND [24], Mammalian MIPS [25], HPRD [26], MINT
[27] and BioGRID [28]. From each database we retrieved the
complete set of available human protein interactions. Table S1
provides the number of protein interactions obtained from each
database by the time of this study. We integrated the different data
sets by mapping the interacting proteins to unique protein
identifiers from UniProt [29] or EntrezGene [30] and thus
generating one comprehensive protein interaction map for our
study. The integrated protein interaction set comprises 13,494
human proteins and 43,637 unique interactions observed between
these proteins. Each protein included in the interaction map is
associated with its respective protein domain information [31] and
functional Gene Ontology (GO) annotations [32] (also retrieved
from UniProt and EntrezGene).
HIV receptor network
We generate a specific HIV receptor network using known
receptors as seeds (see Table 1). We map each seed gene to its
protein(s) thus growing a network around them [33]. The network
is extended by adding proteins that either directly interact with
any seed or that are functionally similar to at least one seed.
Functional similarity between two proteins is determined by using
a semantic similarity measure proposed by Couto et al. [34]. The
formal definition of functional similarity is provided in the Text
S1. In principle, proteins are considered as functionally similar if
their semantic similarity to a seed protein is above the threshold of
0.7 (averaged across the three GO subontologies: molecular
function, biological process and cellular component). Thereby, we
only consider close and significant biological relationships.
Functionally related proteins are integrated into the network
through weighted edges to the seeds. Edge weights are assigned by
combining a protein interaction and a GO score. The protein
interaction score is either 1 if an interaction is documented
between a protein and a seed, and 0 otherwise. The GO score
ranges between 0 and 1 (see Text S1) depending on the similarity
of the GO annotations between two proteins, whereby 1 indicates
functional equality and 0 indicates maximal functional distance.
Interactions and functional similarities among all non-seed
proteins are also included into the network.
We exploit protein interaction because it strengthens the
relationship between (similar) receptors interacting with the same
ligand. Human interaction data, however, is still incomplete and
will not cover the functional space for our analysis. Therefore, we
also integrate functional data to capture cellular surface proteins
that show significant functional similarity with the seed receptors.
Nevertheless, the functional coverage is still limited and currently
only a fraction of the genome is annotated with pathways,
functions and phenotypes [19]. Hence, we integrate predicted
functions in our framework to functionally enrich proteins that are
weakly or not annotated at all.
Functional enrichment
To functionally enrich the HIV network we apply a network-
based function prediction method to derive additional annotations.
This method compares protein interaction networks across
multiple species to detect evolutionarily and functionally conserved
Figure 1. Conceptual design of our prediction framework. The method consists of three components. I) Compiling ‘‘the seed set’’ from genes/
proteins sharing specific characteristic of interest; II) Forming a network by including direct interaction partners described in database(s) and/or
functionally similar partners; III) Network centrality analysis on the domain-specific similarity network to obtain potential interaction factors (PIFs). The
final step of such an analysis is the experimental validation of PIFs. Confirmed PIFs then can be included in the seed set and the steps I-III can be
repeated for identifying new PIFs.
doi:10.1371/journal.pone.0013139.g001
Receptors of HIV Infection
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(using OrthoMCL [35]) and the detection and assembly of
conserved interactions. Within each conserved subgraph we infer
novel protein functions from orthology relationships across species
and along conserved interactions of neighboring proteins within a
species (Jaeger et al. submitted, see [36] for early work). Predicted
functions are added to the set of confirmed functions to better
characterize proteins that are weakly or not annotated at all. The
functional enrichment increases the final cross-validation recovery
rate up to 30% (see Text S1, Table S2 and Figures S1 and S2 for
detailed comparisons).
HIV network centrality analysis
Network centrality analysis is particularly useful for identifying
key elements in different biological processes. In general, networks
are modeled as mathematical objects called graphs. A graph is an
abstract presentation of a set of objects that are connected by links.
In the most common sense a graph G~(V,E) consists of a finite
set of vertices V and edges E whereas an edge e~(u,v) connects
two vertices u and v. Centrality, on the other hand, is formally
defined as a function C that determines a numerical value C(v) for
every vertex v in a graph. We are interested in the ranking of
vertices of the given graph G, thus we follow the convention that a
vertex u is more important than another vertex v if and only if
C(u)wC(v) [37].
Different centrality measures have been proposed for analyzing
various types of biological networks [37]. Established measures are
degree centrality, closeness centrality, betweenness centrality and
PageRank centrality. Here, we chose PageRank [38] to identify
the most important factors within the HIV receptor network since
the PageRank algorithm assigns numerical scores to each node to
determine its relative importance within the network based on the
assumption that not all relationships are equally important for
determining the centrality of a node. Thus, links to high-scoring
nodes contribute more to the PageRank centrality of a node than
links to low-scoring nodes.
We used the PageRank centrality measure to discover novel
surface membrane factors that are involved in HIV-1 infection.
Accordingly, we rank all proteins with respect to their PageRank
centrality within the network using the igraph library in R [39].
Clearly, we expect the seed receptors to be highly ranked in the
ordered list, since our construction algorithm naturally places
them in a central position. Nevertheless, not all seed receptors are
central, and many non-seed proteins are ranked high. We are
especially interested in the latter since these are promising
candidates for novel surface membrane factors. An appropriate
ranking is essential for deciding which factors should be
investigated further, e.g. in follow-up experiments.
Validation
We validate our method and the results as follows: First, we use
leave-one-out cross-validation to assess the predictive power for
finding novel surface membrane HIV factors. Second, we
determine the statistical significance of our results by comparing
them to a random control set. For cross-validation we remove one
seed receptor from the initial list and try to re-discover this
receptor using our method. We build an HIV receptor network
from the remaining receptors and rank the proteins according to
their centrality within the network. Subsequently, we determine
whether the left-out receptor is re-discovered and at which position
of the ranked list. We repeat this procedure for each seed receptor
and determine the average recovery rate across all receptors.
To determine the statistical significance of the results, we
compare them to two random control sets. The first set, S1,
comprises all proteins from the human interaction network as
candidates resulting in 13,494 proteins. The second set, S2,i s
Table 1. Initial set of HIV seed receptors.
Receptor Receptor type InterPro domains
Ig-like and Other
CD4 Primary receptor for HIV Ag CD4, CD4-extracel, Ig-like, Ig-like fold, Ig C2-set, Ig sub, Ig V-set sub
7-TM GPCR and CCR rcpt
CCR5 Co-receptor with CD4 7TM GPCR Rhodpsn, CC 5 rcpt
CCR3 Alternative co-receptor with CD4 7TM GPCR Rhodpsn, CC 3 rcpt
CCR2 Alternative co-receptor with CD4 7TM GPCR Rhodpsn, CC 2 rcpt, CC 5 rcpt
CCR8 Alternative co-receptor with CD4 7TM GPCR Rhodpsn, CC 8 rcpt
CCR9 Alternative co-receptor with CD4 7TM GPCR Rhodpsn, CC 9 rcpt
CXCR4 Alternative co-receptor with CD4 7TM GPCR Rhodpsn, CXC 4 rcpt
CXCR6 Co-receptor 7TM GPCR Rhodpsn, CXC 6 rcpt
CX3CR1 Co-receptor with CD4 7TM GPCR Rhodpsn, CX3C fract rcpt
7-TM GPCR and Other
APJ Alternative co-receptor 7TM GPCR Rhodpsn, APJ rcpt
GPR1 Alternative co-receptor 7TM GPCR Rhodpsn, GPR1 rcpt
Integrin-a
ITGA4 Co-receptor with CD4 Int alpha beta-p, Integrin alpha, Integrin alpha-2, Integrin alpha C
C-type lectin and Other
DC-SIGN Receptor for HIV AntifreezeII, C-type lectin
List of seed HIV receptors, including the receptor type and their functional domains. Receptors are grouped according to their functional domains (see Figure 5(a) for
the distribution of those domains). A full table including the complete list of references that indicate the association to HIV is provided in Table S5.
doi:10.1371/journal.pone.0013139.t001
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simulating a more informed manual search. To generate this set
we use specific GO annotations that imply a receptor activity (see
Table S3) since there is no general receptor definition indicating
whether a protein is a receptor or not. Thus, S2 is formed by
filtering proteins from the interaction data that are annotated with
at least one of these specific GO terms. This results in 2,512
candidates - covering 12 out of 13 seed receptors (ITGA4 is
missing due to insufficient functional annotation). We randomly
draw m samples from each control set, where m corresponds to the
average number of proteins within the HIV network and
determine whether the known receptors are among the samples.
This is repeated 1,000 times and an average recovery rate is
calculated which is later compared to the recovery rate from our
ranking method.
Results
We have designed a framework for discovering novel surface
membrane factors interacting with HIV-1. To this end, we use
protein interaction, protein function, and network centrality
analysis to determine yet uncharacterized surface membrane
proteins based on their functional similarity and topological
closeness to receptors that are known to interact with HIV.
Our strategy is based on the assumption that proteins, which are
related to known HIV receptors through functional similarity or
direct interaction with the same ligands(s), tend to be part of the
same pathway and often share the same biological function.
Therefore, an enriched HIV receptor network is built from
documented surface membrane factors by populating it with
functionally related proteins that either interact directly with or
show significant functional similarity to any known factor.
Subsequently, all proteins are ranked according to their centrality
within the network. The underlying principle of the centrality
analysis presumes that the most central proteins in a domain-
specific network are likely to be of high functional relevance [40].
Thus, yet undiscovered but prospective surface proteins should
also be central in the network. Highly ranked proteins are
analyzed further to identify potentially novel surface membrane
factors. The key steps of our inference method are illustrated in
Figure 2.
In the following subsections, we first evaluate the performance
of the prediction method. Subsequently, we investigate the most
promising predictions by exploring literature on their functional
domains, expression levels and reported clinical evidence.
Cross-validation
Cross-validation is performed on 13 known HIV receptors to
evaluate the predictive power of the method. Overall, we achieved
a re-discovery rate of 92% (12 out of 13). ITGA4 was not re-
discovered by our method, due to its insufficient annotation and
low functional similarity to the other 12 receptors.
We studied the recovery rates using interaction data and GO
annotation with and without functional enrichment. The com-
parison shows that the total number of re-discovered receptors is
significantly higher when functionally enriched data is employed
(see Text S1, Table S2 and Figure S1 and S2 for detailed results).
Consequently, interaction data in combination with enriched
functional annotation are chosen for further analysis.
The same evaluation was performed using random control sets,
S1 and S2. The random recovery rates are compared to the
network-driven recovery rate to assess the statistical significance.
We determine the fraction of seed receptors that can be discovered
when randomly sampling from the complete protein set (S1) and a
subset including only surface membrane proteins (S2) (see
Methods). On average, we discover 0.69 and 3.4 of the 13 seed
receptors when sampling from S1 and S2, respectively, which
results in random recovery rates of 5.3% and 26.2%. The
comparison of recovery rates shows that the network-driven
recovery rate of 92% is clearly superior to the random recovery
rates of 5.3% and 26.2%. The t-test confirms that the observed
superiority over the control sets is statistically highly significant (p-
valuev2.2e-16) and thus underlines the advantage of our
network-driven strategy over the random approach.
For the prediction of novel surface membrane factors, we
investigate the trade-off between discovering potential candidates
vs. false positives by normalizing the recovery rate by the number
of proteins considered at each rank. Figure 3 compares original
and normalized recovery rates across the prioritized protein list.
The receptor-per-protein ratio is used to assess the probability to
identify new HIV interacting surface proteins. The most
significant discovery ratio is 29% (2/7) considering the top 1%
proteins. The second best discovery ratio is achieved at 3%, where
the probability of rediscovering a known surface membrane factor
is 24% (5/21). Note that the probabilities are estimated from the
cross-validation on known data and therefore provide lower bounds
since all novel findings are counted as false positives.
We used these receptor-per-protein ratios to define a cut-off to
select candidates from the prioritized list. We choose 3% as
threshold, since it presents a sensible trade-off between potential
candidates and false positives (seeabove) while yielding a reasonable
number of novel candidates. Thus, the top 21 proteins in the ranked
list are considered as surface membrane factor candidates.
Predicting novel HIV surface membrane factors
Finally, we consider all 13 known HIV receptors as seeds to
build an HIV receptor network with 739 proteins (726 candidates)
and *80,000 functional relationships (note that during cross-
Figure 2. Illustration of the key steps in the prediction method. Starting from the seed HIV receptors we add proteins that 1) have direct
interaction (blue solid edges) or 2) are functionally similar (green dashed edges) to the known receptors to generate an enriched HIV receptor
network. Proteins are ranked according to their centrality within the receptor network. Proteins in shaded areas represent highly central proteins.
doi:10.1371/journal.pone.0013139.g002
Receptors of HIV Infection
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PageRank algorithm and obtained a list of centrality-ranked
proteins. Seed receptors are removed from the list since they are
(by definition) highly ranked. We apply the chosen threshold and
consider the first 21 proteins as host factor candidates. Table 2
presents the top-ranked candidates including their InterPro
domains and cell types.
Figure 4 shows the subnetwork from the full HIV receptor
network that exhibits only the direct functional relationships
between seed receptors and predicted surface membrane factors.
The analysis of the known and predicted surface membrane factors
regarding their annotated KEGG pathways [41] revealed the
involvement of three pathways, namely the chemokine signaling
pathway (hsa04062), the hematopoietic cell lineage (hsa04640) and
the intestinal immune network for IgA production (hsa04672).
Support for predictions
We assess the relevancy of the candidates using evidence that
supports an association with HIV. We investigate the predictions
with respect to functional domains, cell types, expression levels,
associated SNPs and chromosomal locations.
Receptor domains. We analyze our predictions by
comparing their functional protein domains to the domains of
the known seed receptors assuming that overlapping functional
domains indicate similar protein properties, e.g. binding the same
ligand, and functional similarity [42]. Common protein domains
of the seed receptors are:
1. G-protein-coupled receptors (GPCR) rhodopsin-like superfam-
ily and 7 transmembrane (7-TM) GPCR rhodopsin-like
domains (7-TM GPCR)
2. Chemokine receptor domains (CCR rcpt)
3. Immunoglobulin and related domains (Ig-like)
4. C-type lectin and related domains (C-type lectin like)
5. Integrin alpha and related domains (Integrin alpha). The
distribution of the domains among the seed receptors is shown
in Figure 5(a).
Predicted surface membrane factors are grouped according to
their functional domains (see Table 2) which results in GPCR with
chemokine domains, GPCR without chemokine domains, Ig-like
receptors and receptors without any overlapping domains. The
respective domain distribution is displayed in Figure 5(b). The
largest domain overlap is found for 7-TM GPCR rhodopsin-like
domains. Half of the predictions have this particular domain,
which is also overrepresented in the set of seed receptors (10 of 13,
see Figure 5(a)). In addition, CCR1 and CCBP2 share a
chemokine domain, which is very frequent in the set of initial
receptors (8 of 13). Moreover, five predicted surface membrane
factors have Ig-like domains that match the primary HIV receptor
CD4.
The amount of overlapping functional domains indicates that
the functional characteristics of the initial HIV binding receptors
are reflected in predicted surface factors. In particular, GPCRs
have a broad usage spectrum as co-receptors by primary isolates of
HIV [21] and specifically chemokine receptors are known as co-
receptors for HIV [43]. Strikingly, CCR1 and CCBP2 share both
7-TM GPCR rhodopsin-like and chemokine domains and are
reported as co-receptors of HIV. However, receptors without any
overlapping domains might present unprecedented characteristics
that are not documented in the initial set but are reflected in their
complementary domain diversity (see Figure 5(b)).
Figure 3. Results of the leave-one-out cross-validation over the 13 seed receptors. The average receptor re-discovery rate is determined
for the different ranks (in %) of the HIV network. The original re-discovery rate (left y-axis and solid line) is compared to the normalized re-discovery
rate (right y-axis and dashed line). The red dashed line indicates the chosen cut-off. The x-axis is in log-scale to focus on the highest ranks (1% to 5%).
doi:10.1371/journal.pone.0013139.g003
Receptors of HIV Infection
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sometimes located in the same regions of the human genome.
Thus, the genomic location of a gene is often taken into account
when new candidate genes are associated with a disease. The
reason is that mapping those candidates to a region containing
other genes associated to the same disease further supports the
association. For example, HIV binding human CC chemokine
receptor genes are known to cluster within the 3p21.3 region of the
genome [44].
We determine the chromosomal location of the predicted
surface proteins and study whether they cluster together with other
candidates or known seed factors. The chromosomal location for
each seed and prediction retrieved from EntrezGene is shown in
Table S4. When considering the known receptors there is a group
of six chemokine receptors that map to the CCR cluster within
3p21.3, and also two receptors, CCR1 and CCBP2, from the
predicted set are associated to this region. However, the remaining
ones are located on different chromosomes and do not map
together. Only CD97 and DC-SIGN, and GPR17 and CXCR4
are mapped together to 19p13 and 2q21, respectively.
Discussion
The involvement of co-receptors and surface membrane
proteins assisting HIV-1 infection and contributing to viral
pathogenesis always has been underestimated [21]. Only a limited
Table 2. List of inferred surface membrane factors.
Receptor Receptor-specific InterPro domains Cell types
Association
with HIV
7-TM GPCR and Other
HTR6 Not applicable Uniform expression
1 +
HTR1B 5HT1B rcpt Uniform expression
1 ?
HTR1E 5HT1F rcpt Uniform expression
1 ?
RXFP2 LDL rcpt classA cys-rich rpt, Leu-rich rpt, LRR-contain N,
Leu-rich rpt typical-subtyp, Relaxin rcpt
Low expression ?
RXFP1 LDL rcpt classA cys-rich, Leu-rich rpt, LRR-contain N,
Leu-rich rpt typical-subtyp, Relaxin rcpt
No expression profiles available ?
GPR17 P2 purnocptor Uniform expression
1 ?
GPR182 G10D rcpt Uniform expression
1 ?
NPBWR2 Neuropept W rcpt Uniform expression
1 2
7-TM GPCR and CCR rcpt
CCR1 CC 1 rcpt High expression: whole blood,
monocytes, myeloid, dendritic cell
+
CCBP2 CXC 4 rcpt Uniform expression
1 +/2
7-TM GPCR
DARC Duffy cmk rcpt High expression: (early) erythroid, endothelial cells +
Ig-like and Other
CD2 Ag CD2, Ig-like fold, Ig C2-set, Ig V-set, T-cell sdhesion molc CD2 High expression: dendritic, myeloid, monocytes,
NK, CD8 and CD4 T cells, whole blood
+
CSF3R FN III, Hematopoietin rcpt gp130 CS, IgC2-like lig-bd High expression: myeloid cells,
monocytes and whole blood
+
IL1R1 Ig, Ig-like fold, Ig sub, IL1 rcpt 1, IL1R rcpt No expression profile available 2
CD79B Ig-like fold, Ig sub, Ig V-set, Phos immunorcpt sig ITAM High expression: CD34, endothelial
and dendritic cells
+
IL6ST FN III, Hematopoietin rcpt gp130 CS, Ig-like fold, IgC2-like lig-bd Uniform expression
1 +
TNFR Cys rich reg and Other
TNFRSF5 Fas rcpt High expression: B lymphoblasts +
TNFRSF3 TNFR 3 LTBR High expression: myeloid,
monocytes and whole blood
+
Other
CD97 EGF-type Asp/Asn hydroxyl site, EGF Ca bd 2, GPCR 2 CD97,
GPCR 2 secretin-like, GPS dom
High expression: CD34, B lymphoblast, dendritic
cells, CD8 and CD4 T-cells, NK, myeloid, monocytes
+
GP1BB LRR-contain N, Cys-rich flank reg C High expression: CD34, monocytes
and whole blood
?
GYPB Glycophorin High expression: (early) erythroid
and endothelial cells
?
List of the potential surface membrane proteins that result from our method, including functional domains and cell types. Predictions that are associated with HIV in
earlier studies are marked with ‘+’. ‘2’ indicates predictions with negative evidence. For predictions without literature on interaction the association remains unclear
(shown by ‘?’). The list of supporting references is provided in Table S6.
1Uniform expression in CD34, endothelial, B lymphoblasts, dendritic, myeloid, monocytes, NK, CD8 and CD4 T cells, and whole blood.
doi:10.1371/journal.pone.0013139.t002
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factors interacting with viral proteins even though they are
potential amenable drug targets for HIV therapeutics [45,46].
We predict 21 surface membrane HIV factors that are
potentially involved in the different stages of infection influencing
the progression of the disease. Remarkably, among these cell
surface proteins, three have confirmed functions in HIV infection,
seven have been reported by at least two other studies and eleven
predictions are novel findings that deserve experimental investi-
gation. It is important to note that the high success rate of our
method, as shown using cross-validation, strongly implicates that
our predictions can be the missing piece of the puzzle.
Figure 4. Subnetwork of the generated HIV receptor network. The subnetwork focuses on the functional relationships between the seed
receptors (red) and the predicted surface membrane proteins (yellow) within the HIV receptor network. Non-seeds and non-candidate proteins are
not shown confusion. Significantly enriched pathways within this subnetwork are additionally highlighted.
doi:10.1371/journal.pone.0013139.g004
Figure 5. Overview on the distribution of protein domains. Distribution of the protein domains for (a) seed receptors and (b) predicted
surface membrane factors.
doi:10.1371/journal.pone.0013139.g005
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CCR1. The C-C chemokine receptor type 1 is a GPCR that
mediates signal transduction and the recruitment of effector
immune cells to inflammation sites. It is highly expressed in
immune system cells, such as myeloids, monocytes, dendritic cells
and whole blood. Independent studies confirmed the usage of
CCR1 along with CD4 for the entry of HIV into target cells
[21,47].
CCBP2. The Chemokine-binding protein 2 is another
chemokine receptor that is documented to function as
alternative co-receptor for HIV [48].
DARC. The Duffy antigen/chemokine receptor belongs to
the family of erythrocyte chemokine receptors that bind
chemokines. It is highly expressed on red blood cells (RBCs).
Several studies demonstrated the binding of HIV-1 to RBCs
through DARC enabling RBCs to transmit HIV to peripheral
blood mononuclear cells. However, binding HIV to DARC does
not permit viral entry but retains the virus viability and mediates
trans-infection of HIV-1 from RBCs to susceptible T cells [49,50].
Recently, He et al. reported that the DARC 246C/C genotype is
associated with an increase of 40% in the odds of acquiring HIV-1
in African Americans [50]. However, follow-up studies on different
cohorts [51–53] or with correction for population stratification
[54] could not establish a significant association of this DARC
polymorphism and the increased risk for HIV-1 acquisition or
disease progression. Although DARC’s association with HIV has
been established some questions remain regarding its influence on
HIV-1 acquisition and progression.
Prediction with direct and indirect experimental support
CD97. It belongs to the EGF-TM7 family of class II 7-TM
molecules and is present on the surface of most activated
leukocytes. It is broadly expressed on most hematopetic cells,
activated lymphocytes, macrophages, dendritic cells, granulocytes,
monocytes and undergoes a rapid up-regulation during T and B
cells activation. Recently, CD97 was identified in a large-scale
genome RNAi screening as one of six uncharacterized host factors
that are required for HIV replication [45] suggesting its crucial
post-integration role. Furthermore, Kop et al. [55] showed that
CD97 is present on the surface of all human lymphocytes in blood
and lymphoid tissue and confirm its up-regulation upon cellular
activation. In addition, they demonstrated significant differences in
the expression levels between lymphocytes. For instance, T and
NK cells possess higher levels of CD97 than B cells and memory
CD4+ (but not CD8+) T cells express more CD97 than naı ¨ve cells.
These differences might present the missing factor that is required
for active infection of naı ¨ve T cells in early infection because
CD97 is highly expressed in activated memory CD4+ cells but not
in naı ¨ve subsets. To confirm this hypothesis longitudinal testing of
in-vivo expression of CD97 is necessary in patients going through
co-receptor switch.
CSF3R. The granulocyte colony-stimulating factor receptor is
the receptor for colony stimulating factor 3 (G-CSF), a cytokine
that controls the production, differentiation, and function of
granulocytes. CSF3R is highly expressed on monocytes and
activated T cells [56]. Its ligand modulates cytokine production in
monocytes and lymphocytes. In particular, CSF3R is thought to
play a role after viral DNA synthesis. The indirect influence on
infection and replication in human cells has been demonstrated
through the binding of recombinant G-CSF (rG-CSF). rG-CSF is
able to activate replication of HIV-1 during hematopoietic stem
cell mobilization in HIV-1 infected persons [57] and stimulates
viral production through binding to CSF3R that is expressed on
HIV-1 chronically infected cell lines [58]. The direct impact of
CSF3R on HIV replication has been documented recently [46].
Besides, CSF3R has been linked to the developing congenital
neutropenia [59]. This is particularly interesting since DARC has
also been associated with benign ethnic neutropenia observed in
people with African descent [60]. Thus, we hypothesize that in
addition to the genetic predisposition of DARC, CSF3R can
account for the observed differences in HIV induced neutropenia.
TNFRSF3. Also known as Lymphotoxin-beta receptor (LT-
bR), is a member of the tumor necrosis factor (TNF) receptor
superfamily that participates in the regulation of immune and
inflammatory responses by propagating signals that regulate cell
survival or death through activation of NF-kB [61]. LT-bRi s
expressed on myeloids, dendritic cells and monocytes, which play
a critical role in the progression towards AIDS by providing a
major source and reservoir of virus when the T cell population is
depleted [12,62]. Signaling through LT-bR via its ligand LT-b
stimulates viral replication within infected monocytes [63].
TNFRSF5 (CD40). CD40 is a type I membrane glycoprotein
of TNF receptor superfamily and is expressed on B-lymphocytes.
Its ligand CD40L is expressed mainly in activated CD4+ T
lymphocytes. The interaction between CD40 and CD40L leads to
the activation and differentiation of B-lymphocytes [64]. This
mechanism constitutes a non-redundant central role in humoral
and cell-mediated immunity. Early studies identified a link
between CD40L expression and progression to AIDS [65].
Recently it has been demonstrated that HIV-1 promotes CD4+
T cell infection by inserting CD40L into emerging viral particles
and trans-activating B cells in a CD40 dependent manner [66].
CD2. It is typically expressed on T cells and most CD3-
Natural Killer (NK) cells. It mediates intracellular adhesion in T
lymphocytes and targets cells for lysis in NK cells. CD2 has a
pivotal role in activating and inducing latent HIV-1 replication in
resting CD4+ T cells through the CD2 pathway [67]. The CD2
pathway is also reported to increase HIV production in-vivo [68].
Moreover, a longitudinal study on ‘Highly active antiretroviral
therapy’ over a three-year period showed a significant increase of
CD2 expression on peripheral blood mononuclear cells as well as a
slight increase in viral load over the same period [69].
IL6ST (GP130). The Glycoprotein 130 is a transmembrane
protein that controls the activity of cytokines, such as IL- 6, IL-11,
IL-27 and leukemia inhibitory factor (LIF) [70]. It is expressed in
many tissues ranging from gut epithelia to astrocytes and T cell
subsets. GP130 was associated with HIV when studying LIF’s
protective role against vertical transmission of HIV-1 from mother
to child [71]. Both are significantly up-regulated in lymphoid tissue
[72] and found in high concentrations in plasma samples of
patients [73] during primary HIV-1 infection.
Moreover, GP130 is involved in differentiation among T-helper
cell (Th) subsets. A lack of GP130 in T cell specific conditional
gp130 deficient mice models causes the activation of Th2 and
regulatory T cell pathways [70]. In the case of HIV infection, this
change in T cell differentiation dynamics may be responsible for
various levels of disease progression observed in different
individuals. The imbalance of Th subsets is also a strong predictor
of pathogenic SIV infection in primate models [74]. Similarly,
successful CD4+ T cell restoration was associated with enhanced
Th17 CD4+ T cell accumulation when comparing gut associated
lymphoid tissue recovery rates from HIV infected individuals
[75,76].
CD79B (B29, IGB). CD79 is a transmembrane protein that
forms a complex with the B-cell receptor (BCR) and generates a
signal following recognition of an antigen by the BCR. It is
expressed almost exclusively on B cells and B-cells neoplasms [76].
It is composed of two distinct chains called CD79A and CD79B.
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development [77]. HIV Gp120 is documented to down-regulate
CD79B [78] but its underlying mechanism is not yet understood.
In theory, down-regulation of CD79B leads to reduced capacity of
B-cells to bind antigens and more importantly to a decrease in
HIV specific antibody formation [79].
We are aware of the difficulties for implicating HIV-1 strains
efficiently using alternative co-receptors for infection of transfected
cells. Experimental testing usually requires coculturing of virus
strains showing broad co-receptor usage [13,21,80] with appro-
priate transfected cell lines. However, we believe that this effort is
necessary for unraveling potential causes underlying confounding
traits of HIV-1 infection.
Conclusions
We use a systems biology framework that integrates protein
interactions, functional annotation and protein domains for
inferring surface membrane factors interacting with HIV. The
analysis of our predictions confirms that surface membrane
proteins, even though are targeted under different conditions,
are likely to be part of the same functional pathways.
We infer ten surface proteins that are involved in a cascade of
events in HIV infection. Their involvement ranges from serving as
co-receptors for cell entry (CCR1 and CCBP2), mediating trans-
infection (DARC), activating immune cells (CD97) to inducing
viral production from latently infected cells (CSF3R, TNFRSF3
and CD2).
We also present eleven original predictions that are potential
HIV interacting factors (see Table 2). In particular, the platelet
glycoprotein Ib (GPIb) is a surface membrane protein of platelets.
Mutations in the GPIb beta subunit are associated with Bernard-
Soulier syndrome which is characterized by thrombocytopenia,
circulating giant platelets, and prolonged bleeding time [81]. We
speculate that the prolonged interaction of blood platelet expressed
GP1BB with HIV might be responsible for thrombocytopenia
observed in HIV infection. Furthermore, the relaxin receptors
RXFP1 and RXFP2 are known to be expressed on the acrosome
of elongated spermatids [82,83]. Their intron rich gene organi-
zation indicates alternatively spliced variants. This suggests the
existence of different protein isoforms that contribute to their
diverse expression in-vivo. Their association with HIV might
explain the different rates of evolution observed in seminal versus
blood plasma of infected patients [84]. Moreover, either one or
both receptors might be involved in viral hijacking of the
spermatozoa in viral transmission [85].
Several seed receptors, such as CCR5, CCR2 and CX3CR1
[86,87], have been associated with SNPs that contribute to
different disease outcome. Among the 21 predicted factors, except
for the controversial 246C/C in DARC, SNPs in CCR1, CCBP2,
HTR6, HTR1B, HTR1E, CSF3R, IL1R1, TNFRSF5 are
associated with one or more clinical phenotypes but their relation
to HIV infection has not been investigated. Thus, we encourage
investigating the SNPs from the predicted surface membrane
factors for association with HIV to study their potential effect on
HIV infection.
Throughout the manuscript we have presented a novel method
and its application for identifying surface membrane factors for
HIV-1. However, we emphasize that the presented framework is
neither domain nor disease specific. More precisely, our approach is
only depending on the initial (seed) data that is used to establish
characteristic functional similarities. Thus, it can be employed for
many biological questions other than the one discussed in this
manuscript. Potential further applications include, for instance,
clinical genetic studies for determining the downstreamcomponents
of recently discovered disease genes, or drug-target testing for
investigating possible effects/interactions of candidate compounds
with proteins other than the intended targets.
Consequently, in this manuscript we present promising surface
membrane factors that are potentially involved in HIV-1 infection.
Testing these novel hypotheses with target-oriented in-vivo
experiments is crucial to fully understand their impact on HIV-1
infection.
Supporting Information
Figure S1 Comparison of the cross-validation results over the 13
seed receptors for the different HIV receptor network types with (i)
interaction data only (PPI), (ii) interaction data and manual
functional annotations (PPI+GO) and (iii) interaction data in
combination with enriched functional annotation (manually
curated and predicted function) (PPI+GO enrich).
Found at: doi:10.1371/journal.pone.0013139.s001 (0.54 MB TIF)
Figure S2 Original rediscovery rates (left y-axis and solid lines)
across the ranked list in comparison to the normalized rediscovery
rates (right y-axis and dashed lines) for PPI+GO and PPI+GO
enrich. The x-axis is in log-scale to focus on the higher resolution
of the top ranks.
Found at: doi:10.1371/journal.pone.0013139.s002 (0.15 MB TIF)
Table S1 The number of human protein interactions retrieved
from each database by the time of our study.
Found at: doi:10.1371/journal.pone.0013139.s003 (0.05 MB
PDF)
Table S2 Average number of proteins (network size) comprised
in each network and the number of seeds that are rediscovered
during cross-validation when considering different data for
generating the specific HIV receptor network.
Found at: doi:10.1371/journal.pone.0013139.s004 (0.01 MB
PDF)
Table S3 List of functional annotation from Gene Ontology that
are used to filter for receptor proteins for the control sets.
Found at: doi:10.1371/journal.pone.0013139.s005 (0.01 MB
PDF)
Table S4 Chromosomal location of known and predicted
surface membrane proteins. Similar chromosome regions are
colored similarly.
Found at: doi:10.1371/journal.pone.0013139.s006 (0.02 MB
PDF)
Table S5 List of seed HIV receptors, including receptor name
and type, their functional domains and references indicating an
association with HIV-1 infection.
Found at: doi:10.1371/journal.pone.0013139.s007 (0.07 MB
PDF)
Table S6 List of the potential HIV surface membrane factors
inferred by our method, including their functional domains, cell
types and references assessing an association with HIV.
Found at: doi:10.1371/journal.pone.0013139.s008 (0.20 MB
PDF)
Text S1 Definition of functional similarity and description of the
different HIV receptor network types generated from different
functional data, including a detailed performance comparison of
their ability to infer novel surface membrane factors interacting
with HIV-1.
Found at: doi:10.1371/journal.pone.0013139.s009 (0.06 MB
PDF)
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